Hiroyuki Suzuki

Associate professor

Tohoku University

Japan

Research Interests

Explore related searches

Professors in Japan Professors in Immunology Immunology professors in Japan

Contact this professor

ORCID

Google Scholar

About

Hiroyuki Suzuki is an Associate Professor at Tohoku University in Japan. His research primarily focuses on antitumor monoclonal antibodies and their efficacy in various cancer models, including gastric, colorectal, pancreatic, and triple-negative breast cancer. Dr. Suzuki's recent publications highlight his work on targeted therapies and their potential in improving cancer treatment outcomes.

Hiroyuki Suzuki

Research Interests

Explore related searches

Contact this professor

About

Articles (21)

Antitumor Activity by an Anti-CD44 Variant 9 Monoclonal Antibody in Gastric and Colorectal Cancer Xenograft Models

A Cancer-Specific Anti-Podocalyxin Monoclonal Antibody (humPcMab-60) Demonstrated Antitumor Efficacy in Pancreatic and Colorectal Cancer Xenograft Models

EphB2-Targeting Monoclonal Antibodies Exerted Antitumor Activities in Triple-Negative Breast Cancer and Lung Mesothelioma Xenograft Models

Antitumor Activities of a Humanized Cancer-Specific Anti-HER2 Monoclonal Antibody, humH<sub>2</sub>Mab-250 in Human Breast Cancer Xenografts

Anti-CD44 Variant 10 Monoclonal Antibody Exerts Antitumor Activity in Mouse Xenograft Models of Oral Squamous Cell Carcinomas

Anti-HER2 Cancer-Specific mAb, H<sub>2</sub>Mab-250-hG<sub>1</sub>, Possesses Higher Complement-Dependent Cytotoxicity than Trastuzumab

A Cancer-Specific Monoclonal Antibody against HER2 Exerts Antitumor Activities in Human Breast Cancer Xenograft Models

A Cancer-Specific Anti-Podoplanin Monoclonal Antibody, PMab-117-mG<sub>2a</sub> Exerts Antitumor Activities in Human Tumor Xenograft Models

Development of Highly Sensitive Anti-Mouse HER2 Monoclonal Antibodies for Flow Cytometry

Development of a Novel Anti-CD44 Variant 8 Monoclonal Antibody C<sub>44</sub>Mab-94 against Gastric Carcinomas

EMab-300 Detects Mouse Epidermal Growth Factor Receptor-Expressing Cancer Cell Lines in Flow Cytometry

Establishment of a Novel Anti-CD44 Variant 10 Monoclonal Antibody C<sub>44</sub>Mab-18 for Immunohistochemical Analysis against Oral Squamous Cell Carcinomas

A Novel Anti-CD44 Variant 3 Monoclonal Antibody C<sub>44</sub>Mab-6 Was Established for Multiple Applications

A Novel Anti-CD44 Variant 9 Monoclonal Antibody C<sub>44</sub>Mab-1 Was Developed for Immunohistochemical Analyses against Colorectal Cancers

Development of a Novel Anti-CD44 Variant 5 Monoclonal Antibody C<sub>44</sub>Mab-3 for Multiple Applications against Pancreatic Carcinomas

Development of a Novel Anti-CD44 Variant 7/8 Monoclonal Antibody, C<sub>44</sub>Mab-34, for Multiple Applications against Oral Carcinomas

Identification of the Binding Epitope of an Anti-Mouse CCR6 Monoclonal Antibody (C<sub>6</sub>Mab-13) Using 1× Alanine Scanning

Development of a Novel Anti-CD44 Variant 4 Monoclonal Antibody C<sub>44</sub>Mab-108 for Immunohistochemistry

A Cancer-Specific Monoclonal Antibody against Podocalyxin Exerted Antitumor Activities in Pancreatic Cancer Xenografts

A Humanized and Defucosylated Antibody against Podoplanin (humLpMab-23-f) Exerts Antitumor Activities in Human Lung Cancer and Glioblastoma Xenograft Models

Defucosylated Monoclonal Antibody (H<sub>2</sub>Mab-139-mG<sub>2a</sub>-f) Exerted Antitumor Activities in Mouse Xenograft Models of Breast Cancers against Human Epidermal Growth Factor Receptor 2

Collaborators (4)

Manabu Kawada

Yukinari Kato

Mika K. Kaneko

Tomokazu Ohishi

How do I reach out?

Meet Kite AI